Company profile: JPT Peptide Technologies
1.1 - Company Overview
Company description
- Provider of innovative peptide products and services for immunotherapy, immunology, proteomics, and enzyme profiling. ISO 9001 certified, JPT offers custom peptide synthesis with diverse formats and modifications (e.g., fluorescent labels, biotinylation, glycosylation), plus peptide analysis services including stability testing, peptide content determination, and cell toxicity testing. Headquartered and producing in Berlin, Germany.
Products and services
- Custom Peptide Synthesis: JPT engineers tailored peptides in various formats with specific modifications to meet immunotherapy, immunology, proteomics, and clinical research needs, backed by ISO 9001-certified production
- Peptide Modifications: JPT creates peptides with fluorescent labels, biotinylation, and glycosylation to enhance stability and functionality for immunology, proteomics, and enzyme profiling applications, executed under ISO 9001-certified processes
- Peptide Analysis Services: JPT delivers stability testing, peptide content determination, and cell toxicity testing to ensure peptide quality and functionality for immunotherapy and proteomics studies, performed within ISO 9001-certified workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to JPT Peptide Technologies
Oncodesign
HQ: France
Website
- Description: Provider of precision medicine-driven oncology preclinical CRO services and biopharmaceutical R&D, developing anticancer therapies and leveraging platforms such as Nanocyclix for selective kinase inhibitors and OncoSNIPER AI for resistant patient stratification. Pipeline includes OPM-101 (RIPK2, IBD), OPM-102 (RIPK2, inflammation-related tumors), and an LRRK2 program (Parkinson’s), plus the IMODI cluster for cancer models and microbiota studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncodesign company profile →
Medivir
HQ: Sweden
Website
- Description: Provider of research-based pharmaceuticals focused on oncology and infectious diseases, leveraging protease inhibitor design and nucleotide/nucleoside science to address unmet medical needs. Portfolio includes MIV-818 for liver cancer, remetinostat for early-stage MF-CTCL, and VBX-1000 with positive proof-of-concept results. Also offers quarterly report conference calls and investor presentations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medivir company profile →
Quotient Bioresearch
HQ: United Kingdom
Website
- Description: Provider of tailored, integrated radiochemistry, drug metabolism and e-fate solutions as a leading CRO.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quotient Bioresearch company profile →
Curia
HQ: United States
Website
- Description: Provider of contract research, development, and manufacturing services for pharmaceutical and biopharmaceutical customers, covering discovery biology, synthetic and medicinal chemistry, and small-scale and commercial manufacturing. Formerly AMRI, Curia delivers offerings from R&D through commercial manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curia company profile →
Presidio Medical
HQ: United States
Website
- Description: Provider of a transformational neuromodulation platform and ULF Neuromodulation Therapy, which uses ultra low frequency current waveforms to inhibit pain signals; shown effective in clinical trials for chronic pain without causing paresthesia, enabling remedies for disorders affecting neuronal activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Presidio Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for JPT Peptide Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to JPT Peptide Technologies
2.2 - Growth funds investing in similar companies to JPT Peptide Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for JPT Peptide Technologies
4.2 - Public trading comparable groups for JPT Peptide Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →